Ulcerative Colitis Companies

InDex Pharmaceuticals' Viatris-partnered drug fails phase 3 trial setback casts doubt on the potential of this novel therapy, sending InDex's stock plummeting. The news highlights the challenges and uncertainties inherent in drug development.

Takeda's Entyvio encounters safety concerns in new Crohn's disease study While not directly impacting the UC market, this development raises questions about the safety profile of this widely used UC treatment.

Pfizer acquires Via Pharmaceuticals for $6.7 billion deal strengthens Pfizer's position in the gastrointestinal (GI) market, granting them access to Via's promising late-stage UC candidate.

List of Ulcerative Colitis Key Companies in the Market

• Salix Pharmaceuticals


• Abbott Laboratories


• Mitsubishi Tanabe Pharma Corporation


• Celgene Corporation


• InDex Pharmaceuticals Holding AB


• BioLineRx Ltd


• Sanofi Aventis A/S


• Merck & Co


• Eli Lilly


• Johnson & Johnson